期刊文献+

喉癌中P53基因突变与突变型P53基因蛋白表达的相互关系及意义

THE SIGNIFICANCE AND RELATIONSHIP BETWEEN P53 GENE MUTATION AND EXPRESSION OF MUTANT TYPE P53 PROTEIN IN LARYNGEAL CARCINOMAS
暂未订购
导出
摘要 目的:探讨喉癌P53基因突变与突变性P53基因蛋白表达之间的相互关系及意义。方法:对40例喉癌新鲜手术标本采用PCR—SSCP检测P53基因突变,免疫组化方法(LSAB)检测突变型P53基因蛋白表达,并比较其相互间的关系。结果:40例喉癌中有26例基因突变阳性(65%),P53基因蛋白表达阳性者23例(57.5%);P53基因突变与其突变型蛋白表达比较,两者皆阳性为45%,两者均阴性为22.5%,其一致率为67.5%(P<0.05)。结论:P53基因突变与其蛋白表达相吻合。两种检测方法在喉癌的分子病理学诊断及其预后方面同样具有重要的价值。 Objective:To analyse the significance and relationship between p53 gene mutation and the expression of mutant type P53 gene protein in the laryngeal carcinomas.Methods:The fresh tissues of 40 cases of laryngeal carcinomas were used.The mutation of P53 gene was detected by PCR-SSCP and mutant type P53 gene protein was detected by immunohistochemistry staining LSAB method.The results were compared. Results:Out of 40 cases of laryngeal carcinemas,26(65%) showed P53 gene mutation,and 23(57 5%) had positive P53 staining.Comparing the results of PCR SSCP and the staining,both the positive rate was 45% and the negative rate was 22 5%.The concordant rate was 67 5% Conclusion:P53 gene mutation is concordant with protein P53,and P53 immunostaining and SSCP could be used as same as important methods relating to the tumor stage,histopathologic grades and prognosis of laryngeal carcinoma.
出处 《滨州医学院学报》 1999年第2期111-113,共3页 Journal of Binzhou Medical University
关键词 喉癌 基因 P53 基因突变 基因表达 laryngeal carcinoma carcinoma gene P53 gene mutation gene expression
  • 相关文献

参考文献3

二级参考文献10

  • 1Marchetti, Butota P, Merlo G, et al p53 alterations in nonsmall cell lung cancers correlate with metastatic involvement of hilar regional lymph nodes, Cancer Res, 1993,53:2846-2851.
  • 2Ebizn M, Steinberg SM, Mulshine JL. et al. Relationship of p53 overexpression and upregulation of preliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.Cancer Res, 1994,64:2496-2503.
  • 3Passlick B, Izbicki JR, Rrethmuller G, et al. p53 in non-small cell lung cancer. J Natl Cancer Inst,1994,86:801-802.
  • 4Xu HJ, Quinlan DC, Davidson AG. Altered retionblastoma protein expression and prognosis in early-stage non-small cell lung carcinoma. J Natl Cancer Inst, 1994,86:692-699.
  • 5Harris CC, Hollstein M. Clinical implications of the p53 tumor suppression gene. N Engl J Med, 1993,592:1318-1327.
  • 6Battifora H. p53 immunohistochemistry: A word of caution.Hum Pathol, 1994,25:235-436.
  • 7Hall Pa, Lane DP. p53 in tumor pathology: Can we trust immunohistochemistry?Revised! J Pathol, 1994, 172:1-4.
  • 8Batsakis JG, El Naggar AK, p53:fifteen years after discovery Advances in Anatomic Pathology, 1995,2(2):71-88.
  • 9Soussi T, Legros Y, Lubin R, et al Multifactorial analysis of p53 alterations in human cancer: a review. Int J Cancer, 1994,57:1-9.
  • 10Hiroshi Yokozaki,Hiroki Kuniyasu,Yasuhiko Kitadai,Kenji Nishimura,Hiroko Todo,Ay?e Ayhan,Wataru Yasui,Hisao Ito,Eiichi Tahara. p53 point mutations in primary human gastric carcinomas[J] 1992,Journal of Cancer Research and Clinical Oncology(2):67~70

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部